| 摘要: |
| 目的 回顾性分析大环内酯类耐药肺炎支原体(MRMP)感染住院患儿的超药品说明书用药情况,旨在为儿童超药品说明书用药管理提供参考依据旨在推动儿童用药规范,并为超药品说明书用药管理提供参考依据。方法 选取2023年1月至2024年12月陕西某三级综合医院妇女儿童院区儿科收治的164例重症MRMP感染患儿作为研究对象,对其大环内酯类耐药肺炎支原体感染超药品说明书用药使用情况进行收集与统计分析。结果 164例住院患儿年龄范围在7月~15岁,学龄前期及学龄期人群最多;超药品说明书用药品种涉及左氧氟沙星、多西环素、干扰素、布地奈德;超药品说明书用药主要类型为:超出适应证、超适应人群和超给药途径3类,其中超适应人群现象最为普遍。结论 大环内酯类耐药肺炎支原体感染的超药品说明书用药现象较为普遍存在,部分超药品说明书用药伴随着安全和法律风险,亟需规范此类用药行为。建议通过多学科协作规避用药风险,制定医院超药品说明书管理制度减少医疗纠纷,实现合理用药。 |
| 关键词: 儿童 左氧氟沙星 多西环素 大环内酯类耐药肺炎支原体 超药品说明书用药 |
| DOI:10.13506/j.cnki.jpr.2026.09.017 |
| 基金项目:西安国际医学中心医院院级课题(No.2024QN06) |
|
Received Date:December 26, 2025
Revision Date:April 15, 2026
Publication Date:September 30, 2026
|
|
| Analysis of off-label drug use in hospitalized children with macrolide-resistant mycoplasma pneumoniae |
| ZHAO Xu1,TIAN Tian1,GAO Lele2,HONG Shuxia2 |
| (1.Department of Pediatrics,Xi'an International Medical Center hospital,Xi'an 710100China;2.Department of Clinical Pharmacy,Xi'an International Medical Center, Xi'an 710100,China) |
| Abstract: |
| Objective To retrospectively analyze off-label drug use in pediatric inpatients with macrolide-resistant Mycoplasma pneumoniae(MRMP) infection, aiming to provide a reference for managing off-label drug use in pediatric patients. Methods A total of 164 pediatric patients admitted to the Pediatrics Department of the Women and Children's Hospital of a tertiary general hospital in Shaanxi Province from January 2023 to December 2024 were enrolled. Off-label drug use for macrolide-resistant Mycoplasma pneumoniae infection was collected and statistically analyzed. Results The 164 hospitalized patients comprised patients aged from 7 months to 15 years, with the highest prevalence among preschool and school-aged children. Off-label agents included levofloxacin, doxycycline, interferon, and budesonide. The primary categories of off-label drug use were: unapproved indications, unapproved patient populations, and unapproved routes of administration, with off-label drug use unapproved patient populations being the most prevalent. Conclusion Off-label drug use for macrolide-resistant Mycoplasma pneumoniae infections is prevalent. Certain off-label drug uses carry safety and legal risks, necessitating urgent regulation of such practices. Multidisciplinary collaboration is recommended to mitigate medication risks. Establishing institution-wide systems for regulating off-label drug use can reduce medical disputes and promote rational drug use. |
| Key words: Children Levofloxacin Doxycycline Macrolide-resistant Mycoplasma pneumoniae Off-label drug use |